Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes.

Author: FurukawaT, MideraT, MoriY, NukadaT, SagawaT, YamakawaT

Paper Details 
Original Abstract of the Article :
Some dihydropyridines (DHPs), such as amlodipine and cilnidipine, have been shown to block not only L-type but also N-type Ca(2+) channels; therefore, DHPs are no longer considered as L-type-specific Ca(2+) channel blockers. However, selectivity of DHPs for Ca(2+) channel subtypes including N-, P/Q-...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/10525060

データ提供:米国国立医学図書館(NLM)

Understanding the Selectivity of Dihydropyridine Derivatives

Dihydropyridines (DHPs) are a class of medications commonly used to treat cardiovascular conditions. These drugs work by blocking calcium channels, which are essential for the function of heart muscle cells. However, DHPs are not just selective for one type of calcium channel, and their impact on different subtypes of calcium channels is not fully understood.

This research aims to shed light on the selectivity of DHPs for various calcium channel subtypes, including L-, N-, P/Q-, and R-types. The researchers investigated the blocking effects of ten different DHPs on these channel subtypes using a Xenopus oocyte expression system. Their findings showed that while all DHPs effectively blocked L-type channels, their selectivity for other subtypes varied considerably.

DHPs: More Than Just L-Type Blockers

The study revealed that five of the ten DHPs tested significantly blocked N-type and P/Q-type channels. This suggests that DHPs are not simply L-type-specific calcium channel blockers, as previously believed. Understanding these subtype-specific blocking actions is crucial for optimizing their therapeutic use and minimizing potential side effects.

Implications for Drug Development and Patient Care

The findings of this research have important implications for the development of new DHPs with enhanced selectivity for specific calcium channel subtypes. This could lead to more targeted treatments with fewer side effects. Additionally, the study highlights the need for clinicians to consider the potential impact of DHPs on different calcium channel subtypes when prescribing these medications.

Dr. Camel's Conclusion

The world of calcium channels can be as complex as a desert oasis, with its intricate network of interconnected pathways. This research takes us deeper into this complex world, unraveling the intricate interactions between DHPs and different calcium channel subtypes. It reminds us that understanding these nuances is crucial for ensuring effective and safe medical treatment.

Date :
  1. Date Completed 1999-11-24
  2. Date Revised 2006-11-15
Further Info :

Pubmed ID

10525060

DOI: Digital Object Identifier

10525060

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.